United Therapeutics Corp. is eyeing a possible priority review in its anticipated supplemental NDA for Tyvaso (treprostinil) in idiopathic pulmonary fibrosis (IPF) after the second phase III trial hit its endpoints, even besting the impressive findings from the first phase III study reported last year, and positioning United for a substantial commercial launch in 2027.

The K-health MIRAE Initiative, also known as Korean ARPA-H, announced plans to allocate about ₩162 billion (US$110 million) in nine new projects over the next five years, with a focus on strengthening national health security.

The K-health MIRAE Initiative, also known as Korean ARPA-H, announced plans to allocate about ₩162 billion (US$110 million) in nine new projects over the next five years, with a focus on strengthening national health security.

Australian respiratory imaging technology company 4dmedical Ltd. raised AU$150 million (US$105 million) in an institutional placement to accelerate U.S. adoption of its CT:VQ lung imaging software to bolster the company’s lead in software-based lung imaging.

Ebenbuild GmbH is hoping that its digital twin technology platform that combines AI and physics-based computational models tailored to individual patients will transform respiratory care. From drug development to optimizing mechanical ventilation in critical care, the company’s software-based solutions aim to reveal what is happening in the ‘black box’ of the lungs, helping clinicians to improve outcomes and reduce mortality.

As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are growing. Claiming that Kennedy has turned his back on science and is endangering public health, Rep. Haley Stevens, D-Mich., formally introduced articles of impeachment against him Dec. 10 for “high crimes and misdemeanors.” Under the Constitution, federal officials can only be impeached for treason, bribery and “other high crimes and misdemeanors.”

NIH researchers report that in severe influenza, survival improves at late stages only when antivirals are combined with therapies that repair lung damage or limit harmful T-cell responses, explaining why anti-inflammatory treatments alone are often ineffective.

A precision medicine diagnostic system developed by Diag-Nose Medical Pty. Ltd. could potentially transform the management of chronic respiratory diseases. Co-founders Eldin Rostrom, David Yen, Brian Wang and Josie Xu set out to explore why patients with similar respiratory symptoms respond so differently to treatment.

Trials are being conducted at three pediatric emergency departments in England of the Memed BV rapid blood test, designed to help health care providers distinguish between bacterial and viral infections. The test developed by Memed Diagnostics Ltd. can deliver results in as little as 15 minutes, speeding up the diagnosis of serious conditions such as sepsis or meningitis in children.

Private equity firm Keensight Capital acquired a majority stake in Bedfont Scientific Ltd. in a move that will allow the company to expand the use of its devices for breath analysis and monitoring worldwide. Although the value of the deal was undisclosed, Keensight typically invests in profitable companies generating revenues in the range of €10 million to €400 million.